RLMD - NASDAQ

Relmada Therapeutics, Inc.

RLMD·NASDAQ

$6.38

-0.62%

HealthcareBiotechnology

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$467.87M

EPS-1.4500

P/E Ratio-4.40

Earnings Date08/06/2026

rlmd

Net Receivables

Last Annual Value

0.00

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Relmada Therapeutics, Inc. Competitors Analysis of Net Receivables

RLMD · NASDAQ

Company	Net Receivables	CAGR 3Y	CAGR 5Y	CAGR 10Y
Relmada Therapeutics, Inc. NASDAQ:RLMD	0.00	N/A	N/A	N/A
TScan Therapeutics, Inc. NASDAQ:TCRX	0.00	N/A	N/A	N/A
Adicet Bio, Inc. NASDAQ:ACET	342.00K	N/A	9.8%	-46.2%
Vaxart, Inc. NASDAQ:VXRT	51.34M	157.5%	273.1%	56.0%
CAMP4 Therapeutics Corporation NASDAQ:CAMP	155.00K	-29.5%	-69.5%	-45.5%
Clene Inc. NASDAQ:CLNN	0.00	N/A	N/A	N/A
Werewolf Therapeutics, Inc. NASDAQ:HOWL	0.00	N/A	N/A	N/A
Artiva Biotherapeutics, Inc. NASDAQ:ARTV	0.00	N/A	N/A	N/A
Precision BioSciences, Inc. NASDAQ:DTIL	0.00	N/A	N/A	N/A
Prelude Therapeutics Incorporated NASDAQ:PRLD	0.00	N/A	N/A	N/A
Sutro Biopharma, Inc. NASDAQ:STRO	3.98M	-52.1%	-20.4%	21.3%

Relmada Therapeutics, Inc. Fair Value Envelope

RLMD · NASDAQ

Our analysis suggests that RLMD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.38, this represents a potential HIDDEN relative to our calculated worth for Relmada Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $6.38

Related Guides

Blog Categories

Continue your RLMD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.